Beckley Psytech

Beckley Psytech is a clinical-stage biopharmaceutical company dedicated to developing safe, effective, and rapid-acting psychedelic medicines for people suffering from neuropsychiatric disorders. They are driven by a mission to transform psychedelics into licensed medications, and their research is built upon a foundation of over two decades of pioneering scientific research from the Beckley Foundation. Beckley Psytech combines world-leading psychedelic science with extensive drug development expertise, focusing on optimizing patient outcomes and easing the burden of these conditions on individuals and society.

Their pipeline includes BPL-003, a novel synthetic formulation of 5-MeO-DMT administered intranasally, which is currently under investigation in Phase II studies for Treatment Resistant Depression and Alcohol Use Disorder. They are also developing ELE-101, a proprietary intravenous formulation of psilocin, as a potential treatment for Major Depressive Disorder. Beckley Psytech prioritizes patient-centric approaches, fostering collaborations with organizations like PsyPAN to ensure participant well-being and gather valuable insights to improve future trial experiences.

Beckley Psytech is a clinical-stage biopharmaceutical company dedicated to improving the lives of people suffering from neuropsychiatric disorders by transforming psychedelics into effective and licensed medicines. They are focused on developing novel psychedelic therapies to improve patient outcomes and revolutionize treatment for conditions like Treatment Resistant Depression, Alcohol Use Disorder, and Major Depressive Disorder. Their innovative approach combines world-leading psychedelic science with drug development expertise and digital tools to optimize patient outcomes, reduce healthcare resource utilization, and bring meaningful change for patients.

Beckley Psytech fosters a culture centered around scientific rigor, patient-focused innovation, and collaborative action. The company values ethical conduct, a drive to "Get Stuff Done," and a dedication to improving the lives of those suffering from neuropsychiatric disorders. This translates into a fast-paced and growing environment where employees are encouraged to be proactive, innovative, and passionate about their work, ultimately contributing to a shared mission of transforming psychedelics into effective medicines.

Beckley Psytech is committed to fostering a diverse, equitable, and inclusive workplace. They have partnered with PsyPAN, a non-profit focused on improving participant safety and wellbeing by building best practices in the psychedelic sector, to build a Patient Council. The goal of the Patient Council is to draw on patients' lived experiences having taken part in psychedelic trials to co-create and publish participant experience guidance designed to ensure participant safety and wellbeing are put first in research.